Where does Diasorin S.p.A. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Diasorin S.p.A. ranks #26,123 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Diasorin S.p.A. hold?

Diasorin S.p.A. holds 10 US utility patents granted between 2017 and 2023, spanning 6 technology areas.

What is Diasorin S.p.A.'s Innovation Score?

Diasorin S.p.A. has an Innovation Score of 29.4 out of 100 (30th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Diasorin S.p.A.'s patent grant rate increasing or decreasing?

Diasorin S.p.A.'s recent grant velocity is +50% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Diasorin S.p.A.'s patents?

Diasorin S.p.A.'s patents average 17.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Diasorin S.p.A. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Diasorin S.p.A.

Q: What technology areas does Diasorin S.p.A. focus on?

Diasorin S.p.A.'s top technology area is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes) with 6 patents, ranking #717 of 2,502 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

USPTO PatentsView assignee record - 10 granted patents across 6 technology areas, recorded in grant years 2017–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Diasorin ranks #26,123 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 6 technology areas.

#26,123
of 49,997 US assignees by volume: 30th percentile
by Innovation Score (29.4/100): 17.0
avg claims per patent: +50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R26123 · Foreign Corporation #26,123 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #26,123/49,997
PHOTO-FINISH Deutsches Rheuma-for…
CPC-NARROW C12Q · 6 areas
INNOV-THIN 29.4/100
CLAIMS-RICH 17.0 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Deutsches Rheuma-forschungszentrum Berlin (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Diasorin’s 29.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (28%) Velocity 2.2 pts (7%) Breadth 8.7 pts (30%) Claim depth 10.2 pts (35%)

Qualcomm Incorporated · highest

85
Diasorin S p A · this assignee

29
3D Lighting… · lowest

7

What this shows Diasorin's Innovation Score is 29.4/100 (30th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Diasorin?

Each dot is one of Diasorin’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Diasorin’s own 17.0 claims/patent is ABOVE the 15.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Diasorin vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Diasorin's grants concentrate

Diasorin S.p.A. is a focused PatentsView assignee: 6 CPC subclasses with 60% of grants classified under C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2017. By volume, Diasorin sits between Deutsches Rheuma-forschungszentrum Berlin and DNA2.0, Inc..

Diasorin's three-year grant acceleration

Diasorin S.p.A. shows 2 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Deutsches Rheuma-…

10
Devar Entertainme…

10
Devon Energy

10
Diagnostica Stago

10
Digital Check

10
Digiwin

10
Discourse AI

10
DNA2 0

10
Diasorin S p A ◀

10

What this shows Diasorin holds 10 patents at rank #26,103, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Diasorin

By rank, the assignees closest to #26,103 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Diasorin's primary technology class.

Diasorin's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 30th percentile higher than 30% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Diasorin S.p.A. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	10.0%
2018	1	10.0%
2019	2	20.0%
2020	1	10.0%
2021	3	30.0%
2022	1	10.0%
2023	1	10.0%

Which technologies does Diasorin S.p.A. patent most?

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

C07K - Peptides 3

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 1

B01L - Chemical OR Physical Laboratory Apparatus FOR General USE 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Diasorin S.p.A.'s patent record in context - here's where to go next.

Diasorin S.p.A.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 60% of its portfolio - see every assignee active in that class. Explore C12Q
Ranked #26,123 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Diasorin S.p.A. against Deutsches Rheuma-forschungszentrum Berlin, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.